News | May 08, 2026
Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Initiative launched with Tata 1mg to benefit 70,000 people across 70 remote villages in Kalahandi region
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
NEJM study shows strong protection across strains
The leading cancer hospital urges carrier screening to prevent thalassemia burden
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
Subscribe To Our Newsletter & Stay Updated
